doi: 10.1016/s0015-0282(02)03133-3
Hameete 1 , K
Combining peptide enhancement with relationship enrichment produces optimal results
Efficacy and safety of a #biased #GLP-1 receptor agonist #ecnoglutide in adults with #overweight or #obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial thelancet.com/journals/landi Efficacy and safety of a #biased #GLP-1 receptor agonist #ecnoglutide in adults with #overweight or #obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial thelancet.com/journals/landi Linked Comment by Tricia M-M Tan: Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues
The next question is almost always: How much do they cover, and what will you pay out of pocket
Germany is relevant within the European access environment because EMA decisions and payer evidence expectations influence how obesity drugs, diabetes therapeutics and cardiometabolic medicines move from approval to reimbursed use